Adocia

Equities

ADOC

FR0011184241

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 05:29:43 2024-04-25 am EDT			5-day change	1st Jan Change
8.09 ^EUR	-7.54%		-3.80%	-29.90%

Apr. 24	Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 22	Adocia: announces fund-raising	CF

Adocia : AG Presentation

June 04, 2021 at 10:05 am EDT

Shareholders' meeting

May 20th 2021

Adocia - 115, avenue Lacassagne - 69003 Lyon

Speakers

Gérard Soula	Olivier Soula	Valérie
PhD, MBA	PhD, MBA	Danaguézian
President and CEO	Deputy General Manager	Chief Financial Officer
R&D Director

Shareholders' meeting May 20th 2021	2

QUORUM

meeting May 20th

20213

Agenda

Highlights and progress 2020 et H1 2021
Perspectives H2 2021 et 2022
Presentation of the 2020 financial statements
Presentation of the statutory auditors' reports conclusions
Presentation of resolutions and voting results

Shareholders' meeting May 20th 2021	4

2020 overview, Covid context and perspectives

Shareholders' meeting May 20th 2021	5

Attachments

Original document
Permalink

Disclaimer

Adocia SA published this content on 04 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 June 2021 14:04:04 UTC.

Latest news about Adocia

Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Adocia: announces fund-raising	Mar. 22	CF
Adocia SA announced that it expects to receive ?2 million in funding	Mar. 20	CI
Adocia Reveals Promising Preclinical Data on Adocia Islets for Cell Therapy of Diabetes	Nov. 09	CI
Adocia: positive study data for BC Combo	23-10-23	CF
Adocia SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-18	CI
Adocia: refinancing operations completed	23-07-26	CF
Adocia SA announced that it has received ?9.999993 million in funding from Bpifrance Investissement SAS, Vester Finance SA	23-07-19	CI
Adocia: exclusive right to negotiate M1Pram with Sanofi	23-07-06	CF
Sanofi Secures EUR10 Million Exclusivity Deal for Adocia's Diabetes Drug	23-07-06	MT
Adocia Signs an Exclusivity Agreement with Sanofi for M1Pram	23-07-05	CI
Adocia SA announced that it expects to receive â‚¬10 million in funding	23-07-04	CI
Adocia Requests Trading Halt on Euronext Paris	23-06-01	MT
Adocia: listing suspended pending a press release	23-06-01	CF
Adocia SA Auditor Raises 'Going Concern' Doubt	23-04-27	CI
Global markets live: Deliveroo, Adobe, Berkshire Hathaway, First republic Bank, Robinhood Markets...	23-03-16
Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Adocia: CDC drops below 10% stake	23-01-20	CF
Adocia Jumps 11% as BioChaperone Lispro Shows Faster Absorption in Early-stage Insulin Injection Trial	22-12-29	MT
Adocia: share price rises on positive study results	22-12-29	CF
Adocia SA Announces the Successful Phase 1 Study for Biochaperone® Lispro with Partner Tonghua Dongbao	22-12-29	CI
Adocia SA announced that it has received €5.999997 million in funding	22-10-30	CI
Adocia's Phase 2 Study of M1Pram Shows Better Weight Loss, Appetite Control in Diabetic Obese People; Shares Surge 13%	22-10-06	MT
Adocia Sa Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes Using M1pram in A Post-Hoc Analysis	22-10-06	CI
Adocia SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-19	CI

Chart Adocia

Duration

Period

More charts

Company Profile

Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2022, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram-ADO09 and BioChaperone Glucagon) and 3 preclinical-stage products (BioChaperone® LisPram, BioChaperone® Glargine GLP-1 and BioChaperone® Glucagon GLP-1).

Sector

Biotechnology & Medical Research

Calendar

2024-04-28 - LSX World Congress

More about the company

Income Statement Evolution

More financial data

Ratings for Adocia

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

8.75 EUR

Average target price

9.7 EUR

Spread / Average Target

+10.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADOCIA	-29.90%	134M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.31%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.56%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs